Ординатура / Офтальмология / Английские материалы / Ocular Oncology_Albert, Polans_2003

228.Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol Cell Biol 1998; 18:2748–2757.

229.Choubey D, Lengyel P. Binding of an interferon-inducible protein (p202) to the retinoblastoma protein. J Biol Chem 1995; 270:6134–6140.

230.Choubey D, Li SJ, Datta B, Gutterman JU, Lengyel P. Inhibition of E2F-mediated transcription by p202. EMBO J 1996; 15:5668–5678.

231.Xin H, D’Souza S, Fang L, Lengyel P, Choubey D. p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein. Oncogene 2001; 20:6828–6839.

232.Qian Y, Luckey C, Horton L, Esser M, Templeton DJ. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 1992; 12:5363–5372.

233.Riley DJ, Liu CY, Lee WH. Mutations of N-terminal regions render the retinoblastoma protein insufficient for functions in development and tumor suppression. Mol Cell Biol 1997; 17:7342–7352.

234.Dryja TP, Rapaport J, McGee TL, Nork TM, Schwartz TL. Molecular etiology of lowpenetrance retinoblastoma in two pedigrees. Am J Hum Genet 1993; 52:1122–1128.

235.Otterson GA, Chen W, Coxon AB, Khleif SN, Kaye FJ. Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. Proc Natl Acad Sci USA 1997; 94:12036–12040.

236.Xu HJ, Xu K, Zhou Y, Li J, Benedict WF, Hu SX. Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein. Proc Natl Acad Sci USA 1994; 91:9837–9841.

237.Xu HJ, Zhou Y, Seigne J, Perng GS, Mixon M, Zhang C, Li J, Benedict WF, Hu SX. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996; 56:2245– 2249.

238.Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990; 87:2775– 2779.

239.Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP. Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 1991; 353:83–86.

240.Cowell JK, Bia B, Akoulitchev A. A novel mutation in the promotor region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene. Oncogene 1996; 12:431–436.

241.Schubert EL, Strong LC, Hansen MF. A splicing mutation in RB1 in low penetrance retinoblastoma. Hum Genet 1997; 100:557–563.

242.Scheffer H, Van Der Vlies P, Burton M, Verlind E, Moll AC, Imhof SM, Buys CH. Two novel germline mutations of the retinoblastoma gene (RB1) that show incomplete penetrance, one splice site and one missense. J Med Genet 2000; 37:E6.

243.Alonso J, Garcı´a-Miguel P, Abelairas J, Mendiola M, Sarret E, Vendrell MT, Navajas A, Pestan˜a A. Spectrum of germline RB1 gene mutations in Spanish retinoblastoma patients: Phenotypic and molecular epidemiological implications. Hum Mutat 2001; 17:412–422.

244.Onadim Z, Hogg A, Baird PN, Cowell JK. Oncogenic point mutations in exon 20 of the RB1 gene in families showing incomplete penetrance and mild expression of the retinoblastoma phenotype. Proc Natl Acad Sci USA 1992; 89:6177–6181.

245.Lohmann DR, Brandt B, Ho¨pping W, Passarge E, Horsthemke B. Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum Genet 1994; 94:349– 354.

246.Kratzke RA, Otterson GA, Hogg A, Coxon AB, Geradts J, Cowell JK, Kaye FJ. Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 1994; 9:1321–1326.

247.Cowell JK, Bia B. A novel missense mutation in patients from a retinoblastoma pedigree showing only mild expression of the tumor phenotype. Oncogene 1998; 16:3211–3213.

248.Otterson GA, Modi S, Nguyen K, Coxon AB, Kaye FJ. Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families. Am J Hum Genet 1999; 65:1040–1046.

249.Ahmad NN, Barbosa de Melo MD, Singh AD, Donoso LA, Shields JA. A possible hot spot in exon 21 of the retinoblastoma gene predisposing to a low penetrant retinoblastoma phenotype? Ophthalmic Genet 1999; 20:225–231.

250.Harbour JW. Molecular basis of low-penetrance retinoblastoma. Arch Ophthalmol 2001; 119:1699–1704.

251.Strong LC, Riccardi VM, Ferrell RE, Sparkes RS. Familial retinoblastoma and chromosome 13 deletion transmitted via an insertional translocation. Science 1981; 213:1501–1503.

252.Lohmann D, Horsthemke B, Gillessen-Kaesbach G, Stefani FH, Ho¨fler H. Detection of small RB1 gene deletions in retinoblastoma by multiplex PCR and high-resolution gel electrophoresis. Hum Genet 1992; 89:49–53.

253.Gallie BL, Squire JA, Goddard A, Dunn JM, Canton M, Hinton D, Zhu XP, Phillips RA. Mechanism of oncogenesis in retinoblastoma. Lab Invest 1990; 62:394–408.

254.Chen TT, Wang JY. Establishment of irreversible growth arrest in myogenic differentiation requires the RB LXCXE-binding function. Mol Cell Biol 2000; 20:5571–5580.

255.Morgan DO. Principles of CDK regulation. Nature 1995; 374:131–134.

256.Nigg EA. Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. Bioessays 1995; 17:471–480.

257.DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: The disease, gene and protein provide critical leads to understand cancer. Semin Cancer Biol 2000; 10:255–269.

258.Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene 1998; 17:1457–1462.

259.Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000; 57:1613–1636.

260.Takuwa N, Takuwa Y. Regulation of cell cycle molecules by the Ras effector system. Mol Cell Endocrinol 2001; 177:25–33.

261.Ekholm SV, Zickert P, Reed SI, Zetterberg A. Accumulation of cyclin E is not a prerequisite for passage through the restriction point. Mol Cell Biol 2001; 21:3256– 3265.

262.Yen A, Sturgill R. Hypophosphorylation of the RB protein in S and G2 as well as G1 during growth arrest. Exp Cell Res 1998; 241:324–331.

263.Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY. Inhibition of DNA synthesis by RB: effects on G1/S transition and S- phase progression. Genes Dev 1998; 12:2278–2292.

264.Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Mol Cell Biol 2000; 20:7751–7763.

265.Lukas C, Sorensen CS, Kramer E, Santoni-Rugiu E, Lindeneg C, Peters JM, Bartek J, Lukas J. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999; 401:815–818.

266.Harbour JW, Dean DC. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000; 14:2393–2409.

267.Zheng L, Lee WH. The retinoblastoma gene: A prototypic and multifunctional tumor suppressor. Exp Cell Res 2001; 264:2–18.

268.Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, Nevins JR. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 2001; 21:4684–4699.

269.Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC. Linking the Rb and the polycomb pathways. Mol Cell 2001; 8:557–568.

270.Nelson DA, Krucher NA, Ludlow JW. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J Biol Chem 1997; 272:4528– 4535.

271.Nelson DA, Ludlow JW. Characterization of the mitotic phase pRb-directed protein phosphatase activity. Oncogene 1997; 14:2407–2415.

272.Tamrakar S, Ludlow JW. The carboxyl-terminal region of the retinoblastoma protein binds noncompetitively to protein phosphatase type 1alpha and inhibits catalytic activity. J Biol Chem 2000; 275:27784–27789.

273.Cooper S, Yu C, Shayman JA. Phosphorylation-dephosphorylation of retinoblastoma protein not necessary for passage through the mammalian cell division cycle. IUBMB Life 1999; 48:225–230.

274.Cooper S, Shayman JA. Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle. Cell Mol Life Sci 2001; 58:580–595.

275.Alexander K, Hinds PW. Requirement for p27Kip1 in retinoblastoma protein-mediated senescence. Mol Cell Biol 2001; 21:3616–3631.

276.Harrington EA, Bruce JL, Harlow E, Dyson N. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc Natl Acad Sci USA 1998; 95:11945– 11950.

277.Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclindependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA 1999; 96:1002–1007.

278.Ohnuma S, Philpott A, Harris WA. Cell cycle and cell fate in the nervous system. Curr Opin Neurobiol 2001; 11:66–73.

279.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.

280.Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378:F115–177.

281.Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996; 68:67–108.

282.Bruce JL, Hurford RK, Jr., Classon M, Koh J, Dyson N. Requirements for cell cycle arrest by p16Ink4a. Mol Cell 2000; 6:737–742.

283.Beijersbergen RL, Carlee L, Kerkhoven RM, Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev 1995; 9:1340–1353.

284.Xiao ZX, Ginsberg D, Ewen M, Livingston DM. Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases. Proc Natl Acad Sci USA 1996; 93:4633–4637.

285.Dong F, Cress WD, Jr., Agrawal D, Pledger WJ. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. J Biol Chem 1998; 273:6190–6195.

286.Ashizawa S, Nishizawa H, Yamada M, Higashi H, Kondo T, Ozawa H, Kakita A, Hatakeyama M. Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression. J Biol Chem 2001; 276:11362– 11370.

287.Lasorella A, Iavarone A, Israel MA. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 1996; 16:2570–2578.

288.Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone

A.Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. Cancer Res 2002; 62:301–306.

289.Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, Weinberg RA. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 1987; 84:9059–9063.

290.Reissmann PT, Simon MA, Lee WH, Slamon DJ. Studies of the retinoblastoma gene in human sarcomas. Oncogene 1989; 4:839–843.

291.Wunder JS, Czitrom AA, Kandel R, Andrulis IL. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. J Natl Cancer Inst 1991; 83:194–200.

292.Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro

T.Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994; 54:3042–3048.

293.Weichselbaum RR, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 1988; 85:2106–2109.

294.Stratton MR, Williams S, Fisher C, Ball A, Westbury G, Gusterson BA, Fletcher CD, Knight JC, Fung YK, Reeves BR, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer 1989; 60:202–205.

295.Chibon F, Mairal A, Freneaux P, Terrier P, Coindre JM, Sastre X, Aurias A. The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. Cancer Res 2000; 60:6339–6345.

296.Lefevre SH, Vogt N, Dutrillaux AM, Chauveinc L, Stoppa-Lyonnet D, Doz F, Desjardins L, Dutrillaux B, Chevillard S, Malfoy B. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 2001; 20:8092–8099.

297.Karpeh MS, Brennan MF, Cance WG, Woodruff JM, Pollack D, Casper ES, Dudas ME, Latres E, Drobnjak M, Cordon-Cardo C. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer 1995; 72:986–991.

298.Cohen JA, Geradts J. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol 1997; 28:893–898.

299.Dei Tos AP, Maestro R, Doglioni C, Piccinin S, Libera DD, Boiocchi M, Fletcher CD. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol 1996; 148:1037–1045.

300.Derre J, Lagace R, Nicolas A, Mairal A, Chibon F, Coindre JM, Terrier P, Sastre X, Aurias A. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. Lab Invest 2001; 81:211–215.

301.Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene 1991; 6:2305– 2309.

302.Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53:781–784.

303.Bataille V, Hiles R, Newton Bishop JA. Retinoblastoma, melanoma, and the atypical mole syndrome. Br J Dermatol 1995; 132:134–138.

304.Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J. The p16cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475–5483.

305.Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL, Fodstad O. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 1996; 73:909–916.

306.Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 1998; 22:157–163.

307.Halaban R, Cheng E, Smicun Y, Germino J. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. J Exp Med 2000; 191:1005–1016.

308.Halaban R. Melanoma cell autonomous growth: The Rb/E2F pathway. Cancer Metastasis Rev 1999; 18:333–343.

309.Tripathi BJ, Tripathi RC. Development of the human eye. In: Bron AJ, Tripathi RC, Tripathi BJ, eds. Wolff’s anatomy of the eye and orbit. London: Chapman & Hall Medical, 1997.

310.Young RW. Cell differentiation in the retina of the mouse. Anat Rec 1985; 212:199– 205.

311.Davis AA, Matzuk MM, Reh TA. Activin A promotes progenitor differentiation into photoreceptors in rodent retina. Mol Cell Neurosci 2000; 15:11–21.

312.Clarke AR. Murine models of neoplasia: Functional analysis of the tumour suppressor genes Rb-1 and p53. Cancer Metastasis Rev 1995; 14:125–148.

313.Jacks T. Tumor suppressor gene mutations in mice. Annu Rev Genet 1996; 30:603–636.

314.Vooijs M, Berns A. Developmental defects and tumor predisposition in Rb mutant mice. Oncogene 1999; 18:5293–5303.

315.Mills MD, Windle JJ, Albert DM. Retinoblastoma in transgenic mice: Models of hereditary retinoblastoma. Surv Ophthalmol 1999; 43:508–518.

316.Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: Interaction with host proteins. Semin Cancer Biol 2001; 11:15–23.

317.Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20:7874–7887.

318.Zwerschke W, Jansen-Durr P. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv Cancer Res 2000; 78:1–29.

319.Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, Zacny VL. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001; 20:7888–7898.

320.Windle JJ, Albert DM, O’Brien JM, Marcus DM, Disteche CM, Bernards R, Mellon PL. Retinoblastoma in transgenic mice. Nature 1990; 343:665–669.

321.O’Brien JM, Marcus DM, Niffenegger AS, Bernards R, Carpenter JL, Windle JJ, Mellon P, Albert DM. Trilateral retinoblastoma in transgenic mice. Trans Am Ophthalmol Soc 1989; 87:301–326.

322.O’Brien JM, Marcus DM, Bernards R, Carpenter JL, Windle JJ, Mellon P, Albert DM. A transgenic mouse model for trilateral retinoblastoma. Arch Ophthalmol 1990; 108:1145–1151.

323.Marcus DM, Carpenter JL, O’Brien JM, Kivela T, Brauner E, Tarkkanen A, Virtanen I, Albert DM. Primitive neuroectodermal tumor of the midbrain in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci 1991; 32:293–301.

324.Kivela¨T, Virtanen I, Marcus DM, O’Brien JM, Carpenter JL, Brauner E, Tarkkanen A, Albert DM. Neuronal and glial properties of a murine transgenic retinoblastoma model. Am J Pathol 1991; 138:1135–1148.

325.Marcus DM, O’Brien JM, Sahel J, Brauner E, Thor A, Roberts K, Barnstable C, Albert DM. The histogenesis of murine transgenic retinoblastoma (abstract). Invest Ophthalmol Vis Sci 1992; 33 (Suppl):875.

326.Nork TM, Schwartz TL, Doshi HM, Millecchia LL. Retinoblastoma. Cell of origin. Arch Ophthalmol 1995; 113:791–802.

327.Al-Ubaidi MR, Font RL, Quiambao AB, Keener MJ, Liou GI, Overbeek PA, Baehr W. Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoter. J Cell Biol 1992; 119:1681–1687.

328.Howes KA, Lasudry JG, Albert DM, Windle JJ. Photoreceptor cell tumors in transgenic mice. Invest Ophthalmol Vis Sci 1994; 35:342–351.

329.Baetge EE, Behringer RR, Messing A, Brinster RL, Palmiter RD. Transgenic mice express the human phenylethanolamine N- methyltransferase gene in adrenal medulla and retina. Proc Natl Acad Sci USA 1988; 85:3648–3652.

330.Fung KM, Chikaraishi DM, Suri C, Theuring F, Messing A, Albert DM, Lee VM, Trojanowski JQ. Molecular phenotype of simian virus 40 large T antigen-induced primitive neuroectodermal tumors in four different lines of transgenic mice. Lab Invest 1994; 70:114–124.

331.Marcus DM, Lasudry JG, Carpenter JL, Windle J, Howes KA, al-Ubaidi MR, Baehr W, Overbeek PA, Font RL, Albert DM. Trilateral tumors in four lines of transgenic mice expressing SV-40 T-antigen. Invest Ophthalmol Vis Sci 1996; 37:392–396.

332.Al-Ubaidi MR, Hollyfield JG, Overbeek PA, Baehr W. Photoreceptor degeneration induced by the expression of simian virus 40 large tumor antigen in the retina of transgenic mice. Proc Natl Acad Sci USA 1992; 89:1194–1198.

333.Al-Ubaidi MR, Mangini NJ, Quiambao AB, Myers KM, Abler AS, Chang CJ, Tso MO, Butel JS, Hollyfield JG. Unscheduled DNA replication precedes apoptosis of photoreceptors expressing SV40 T antigen. Exp Eye Res 1997; 64:573–585.

334.Porrello K, Bhat SP, Bok D. Detection of interphotoreceptor retinoid binding protein (IRBP) mRNA in human and cone-dominant squirrel retinas by in situ hybridization. J Histochem Cytochem 1991; 39:171–176.

335.Carter-Dawson L, Alvarez RA, Fong SL, Liou GI, Sperling HG, Bridges CD. Rhodopsin, 11-cis vitamin A, and interstitial retinol-binding protein (IRBP) during retinal development in normal and rd mutant mice. Dev Biol 1986; 116:431–438.

336.Yokoyama T, Liou GI, Caldwell RB, Overbeek PA. Photoreceptor-specific activity of the human interphotoreceptor retinoid-binding protein (IRBP) promoter in transgenic mice. Exp Eye Res 1992; 55:225–233.

337.Hammang JP, Baetge EE, Behringer RR, Brinster RL, Palmiter RD, Messing A. Immortalized retinal neurons derived from SV40 T-antigen-induced tumors in transgenic mice. Neuron 1990; 4:775–782.

338.Hammang JP, Behringer RR, Baetge EE, Palmiter RD, Brinster RL, Messing A. Oncogene expression in retinal horizontal cells of transgenic mice results in a cascade of neurodegeneration. Neuron 1993; 10:1197–1209.

339.Cohen J. Postnatal development of phenylethanolamine N-methyltransferase activity of rat retina. Neurosci Lett 1987; 83:138–142.

340.Sidman RL. Histogenesis of mouse retina studied with thymidine-H3. In: Smelser GK, ed. The Structure of the Eye. New York: Academic Press, 1961:487–506.

341.Polley EH, Zimmerman RP, Fortney RL. Neurogenesis and maturation of cell morphology in the development of the mammalian retina. In: Finlay BL, Sengelaub DR, eds. Development of the Vertebrate Retina. New York: Plenum Press, 1987:3–29.

342.Griep AE, Krawcek J, Lee D, Liem A, Albert DM, Carabeo R, Drinkwater N, McCall M, Sattler C, Lasudry JG, Lambert PF. Multiple genetic loci modify risk for retinoblastoma in transgenic mice. Invest Ophthalmol Vis Sci 1998; 39:2723–2732.

343.Howes KA, Ransom N, Papermaster DS, Lasudry JG, Albert DM, Windle JJ. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev 1994; 8:1300–1310.

344.Papermaster DS, Howes K, Ransom N, Windle JJ. Apoptosis of photoreceptors and lens fiber cells with cataract and multiple tumor formation in the eyes of transgenic mice lacking the p53 gene and expressing the HPV 16 E7 gene under the control of the IRBP promoter. In: Anderson RE, LaVail MM, Hollyfield JG, eds. Degenerative Diseases of the Retina. New York: Plenum Press, 1995:39–49.

345.Pan H, Griep AE. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 1995; 9:2157–2169.

346.Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA. Spontaneous abnormalities in normal fibroblasts from patients with LiFraumeni cancer syndrome: Aneuploidy and immortalization. Cancer Res 1990; 50:7979–7984.

347.Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70:923–935.

348.Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70:937–948.

349.Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA. In vitro growth characteristics of embryo fibroblasts isolated from p53deficient mice. Oncogene 1993; 8:2457–2467.

350.Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiationinduced chromosomal abnormalities in p53-deficient mice. Cancer Res 1995; 55:3883– 3889.

351.Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE. Deficiency of p53 accelerates mammary tumorigenesis in Wnt- 1 transgenic mice and promotes chromosomal instability. Genes Dev 1995; 9:882–895.

352.Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D, Donehower LA. Retention of wild-type p53 in tumors from p53 heterozygous mice: Reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17:4657–4667.

353.Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, Varmus HE, Donehower LA. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ 1997; 8:829–838.

354.Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/ þ mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994; 9:1021–1027.

355.Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T. Targeted disruption of p107: Functional overlap between p107 and Rb. Genes Dev 1996; 10:1621–1632.

356.Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev 1996; 10:1633–1644.

357.Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi Y-P, Pinkel D, Gray J, Bradley A, Demina D, Varmus HE. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215–221.

358.Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994; 7:480–484.

359.Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 1996; 10:826–835.

360.Albert DM, Hogan RN. Does retinoblastoma occur in animals? Prog Vet Comp Ophthalmol 1991; 1991:73–82.

361.Syed NA, Nork TM, Poulsen GL, Riis RC, George C, Albert DM. Retinoblastoma in a dog. Arch Ophthalmol 1997; 115:758–763.

362.Oliveros O, Yunis E. Chromosome evolution in retinoblastoma. Cancer Genet Cytogenet 1995; 82:155–160.

363.Chen D, Gallie BL, Squire JA. Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet 2001; 129:57–63.

364.Cano J, Oliveros O, Yunis E. Phenotype variants, malignancy, and additional copies of 6p in retinoblastoma. Cancer Genet Cytogenet 1994; 76:112–115.

365.Mairal A, Pinglier E, Gilbert E, Peter M, Validire P, Desjardins L, Doz F, Aurias A, Couturier J. Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses. Genes Chromosomes Cancer 2000; 28:370–379.

366.Douglass EC, Green AA, Hayes FA, Etcubanas E, Horowitz M, Wilimas JA. Chromosome 1 abnormalities: a common feature of pediatric solid tumors. J Natl Cancer Inst 1985; 75:51–54.

367.Atkin NB. Chromosome 1 aberrations in cancer. Cancer Genet Cytogenet 1986; 21:279–285.

368.Heim S, Mitelman F. Cancer cytogenetics. New York: Wiley-Liss, 1995.

369.Gardner HA, Gallie BL, Knight LA, Phillips RA. Multiple karyotypic changes in retinoblastoma tumor cells: presence of normal chromosome No. 13 in most tumors. Cancer Genet Cytogenet 1982; 6:201–211.

370.Herzog S, Lohmann DR, Buiting K, Schuler A, Horsthemke B, Rehder H, Rieder H. Marked differences in unilateral isolated retinoblastomas from young and older children studied by comparative genomic hybridization. Hum Genet 2001; 108:98–104.

371.Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, Dutrillaux B, Ross D, Malfoy B, Hanash S. GAC1, a new member of the leucine-rich repeat superfamily on chromosome band 1q32.1, is amplified and overexpressed in malignant gliomas. Oncogene 1998; 16:2997–3002.

372.Kusnetsova LE, Prigogina EL, Pogosianz HE, Belkina BM. Similar chromosomal abnormalities in several retinoblastomas. Hum Genet 1982; 61:201–204.

373.Squire J, Phillips RA, Boyce S, Godbout R, Rogers B, Gallie BL. Isochromosome 6p, a unique chromosomal abnormality in retinoblastoma: verification by standard staining techniques, new densitometric methods, and somatic cell hybridization. Hum Genet 1984; 66:46–53.

374.Potluri VR, Helson L, Ellsworth RM, Reid T, Gilbert F. Chromosomal abnormalities in human retinoblastoma. A review. Cancer 1986; 58:663–671.

375.Horsthemke B, Greger V, Becher R, Passarge E. Mechanism of i(6p) formation in retinoblastoma tumor cells. Cancer Genet Cytogenet 1989; 37:95–102.

376.Mertens F, Johansson B, Mitelman F. Isochromosomes in neoplasia. Genes Chromosomes Cancer 1994; 10:221–230.

377.Bruch J, Schulz WA, Haussler J, Melzner I, Bruderlein S, Moller P, Kemmerling R, Vogel W, Hameister H. Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. Cancer Res 2000; 60:4526–4530.

378.Ishikawa J, Xu HJ, Hu SX, Yandell DW, Maeda S, Kamidono S, Benedict WF, Takahashi R. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res 1991; 51:5736–5743.

379.Miyamoto H, Shuin T, Torigoe S, Iwasaki Y, Kubota Y. Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995; 71:831–835.

380.Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knonagel H, Moch H, Mihatsch MJ, Gasser TC, Sauter G. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res 1999; 59:5687– 5691.

381.Tomovska S, Richter J, Suess K, Wagner U, Rozenblum E, Gasser TC, Moch H, Mihatsch MJ, Sauter G, Schraml P. Molecular cytogenetic alterations associated with

rapid tumor cell proliferation in advanced urinary bladder cancer. Int J Oncol 2001; 18:1239–1244.

382.Chen D, Pajovic S, Duckett A, Brown VD, Squire JA, Gallie BL. Genomic amplification in retinoblastoma narrowed to 0.6 megabase on chromosome 6p containing a kinesin-like gene, RBKIN. Cancer Res 2002; 62:967–971.

383.Manning BD, Snyder M. Drivers and passengers wanted! the role of kinesin-associated proteins. Trends Cell Biol 2000; 10:281–289.

384.Nakagawa T, Setou M, Seog D, Ogasawara K, Dohmae N, Takio K, Hirokawa N. A novel motor, KIF13A, transports mannose-6-phosphate receptor to plasma membrane through direct interaction with AP-1 complex. Cell 2000; 103:569–581.

385.De Souza AT, Yamada T, Mills JJ, Jirtle RL. Imprinted genes in liver carcinogenesis. FASEB J 1997; 11:60–67.

386.Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396:177–180.

387.Yagi T, Takeichi M. Cadherin superfamily genes: Functions, genomic organization, and neurologic diversity. Genes Dev 2000; 14:1169–1180.

388.Steinberg MS, McNutt PM. Cadherins and their connections: Adhesion junctions have broader functions. Curr Opin Cell Biol 1999; 11:554–560.

389.Cavallaro U, Schaffhauser B, Christofori G. Cadherins and the tumour progression: Is it all in a switch? Cancer Lett 2002; 176:123–128.

390.Newsham I, Kindler-Rohrborn A, Daub D, Cavenee W. A constitutional BWS-related t(11;16) chromosome translocation occurring in the same region of chromosome 16 implicated in Wilms’ tumors. Genes Chromosomes Cancer 1995; 12:1–7.

391.Austruy E, Candon S, Henry I, Gyapay G, Tournade MF, Mannens M, Callen D, Junien C, Jeanpierre C. Characterization of regions of chromosomes 12 and 16 involved in nephroblastoma tumorigenesis. Genes Chromosomes Cancer 1995; 14:285– 294.

392.Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991; 51:5118–5122.

393.Kaye FJ. Can p53 status resolve paradoxes between human and non-human retinoblastoma models? J Natl Cancer Inst 1997; 89:1476–1477.

394.Schlamp CL, Poulsen GL, Nork TM, Nickells RW. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J Natl Cancer Inst 1997; 89:1530– 1536.

395.Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49–53.

396.Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77:81–137.

397.Kato MV, Shimizu T, Ishizaki K, Kaneko A, Yandell DW, Toguchida J, Sasaki MS. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett 1996; 106:75–82.

398.Nork TM, Poulsen GL, Millecchia LL, Jantz RG, Nickells RW. p53 regulates apoptosis in human retinoblastoma. Arch Ophthalmol 1997; 115:213–219.

399.Doz F, Peter M, Schleiermacher G, Vielh P, Validire P, Putterman M, Blanquet V, Desjardins L, Dufier JL, Zucker JM, Mosseri V, Thomas G, Magdelenat H, Delattre O. N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma. Eur J Cancer 1996; 32A:645–649.

400.Lee WH, Murphree AL, Benedict WF. Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 1984; 309:458–460.

401.Sakai K, Kanda N, Shiloh Y, Donlon T, Schreck R, Shipley J, Dryja T, Chaum E, Chaganti RS, Latt S. Molecular and cytologic analysis of DNA amplification in retinoblastoma. Cancer Genet Cytogenet 1985; 17:95–112.

402.Squire J, Goddard AD, Canton M, Becker A, Phillips RA, Gallie BL. Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature 1986; 322:555–557.

403.Seshadri R, Matthews C, Norris MD, Brian MJ. N-myc amplified in retinoblastoma cell line FMC-RB1. Cancer Genet Cytogenet 1988; 33:25–27.

404.Gupta J, Han LP, Wang P, Gallie BL, Bacchetti S. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 1996; 88:1152–1157.

405.Ewen ME, Xing YG, Lawrence JB, Livingston DM. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 1991; 66:1155–1164.

406.Egan C, Bayley ST, Branton PE. Binding of the Rb1 protein to E1A products is required for adenovirus transformation. Oncogene 1989; 4:383–388.

407.Brantley MA, Jr., Harbour JW. The molecular biology of retinoblastoma. Ocul Immunol Inflamm 2001; 9:1–8.

408.Margo C, Hidayat A, Kopelman J, Zimmerman LE. Retinocytoma. A benign variant of retinoblastoma. Arch Ophthalmol 1983; 101:1519–1531.

409.Balaban G, Gilbert F, Nichols W, Meadows AT, Shields J. Abnormalities of chromosome #13 in retinoblastomas from individuals with normal constitutional karyotypes. Cancer Genet Cytogenet 1982; 6:213–221.

410.Benedict WF, Banerjee A, Mark C, Murphree AL. Nonrandom chromosomal changes in untreated retinoblastomas. Cancer Genet Cytogenet 1983; 10:311–333.

411.Workman ML, Soukup SW. Chromosome features of two retinoblastomas. Cancer Genet Cytogenet 1984; 12:365–370.

412.Chaum E, Ellsworth RM, Abramson DH, Haik BG, Kitchin FD, Chaganti RS. Cytogenetic analysis of retinoblastoma: Evidence for multifocal origin and in vivo gene amplification. Cytogenet Cell Genet 1984; 38:82–91.

413.Squire J, Gallie BL, Phillips RA. A detailed analysis of chromosomal changes in heritable and nonheritable retinoblastoma. Hum Genet 1985; 70:291–301.

414.Yan Y, Dunkel IJ, Guan X, Abramson DH, Jhanwar SC, O’Reilly RJ. Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice. Eur J Cancer 2000; 36:221–228.

415.Naumova A, Hansen M, Strong L, Jones PA, Hadjistilianou D, Mastrangelo D, Griegel S, Rajewsky MF, Shields J, Donoso L, et al. Concordance between parental origin of chromosome 13q loss and chromosome 6p duplication in sporadic retinoblastoma. Am J Hum Genet 1994; 54:274–281.

416.Balaban-Malenbaum G, Gilbert F, Nichols WW, Hill R, Shields J, Meadows AT. A deleted chromosome no. 13 in human retinoblastoma cells: Relevance to tumorigenesis. Cancer Genet Cytogenet 1981; 3:243–250.